Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5716659 | Seminars in Diagnostic Pathology | 2017 | 8 Pages |
Abstract
Hematolymphoid malignancies of the breast are most commonly neoplasms of mature B-lymphocytes, and may arise as a primary disease or by secondary involvement of a systemic disease. Primary breast lymphomas (PBL) account for 0.04-0.5% of breast malignancies, less than 1% of all non-Hodgkin's lymphomas (NHL), and less than 5% of extranodal lymphomas (Lakhani et al., 2012; Swerdlow et al., 2008; Joks et al., 2011; BariÅta et al., 2000; Giardini et al., 1992; Brogi and Harris, 1999; Topalovski et al., 1999).1-7 Secondary breast lymphomas (SBL) are also rare, with an estimated annual incidence of 0.07% (Domchek et al., 2002; Talwalkar et al., 2008).8,9 Recognition of breast lesions as hematolymphoid is critical to distinguish them from other entities that can occur in the breast.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Jenny Hoffmann, Robert S. Ohgami,